sb 202190 has been researched along with Intraocular Pressure in 1 studies
4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole: structure given in first source; inhibits p38 MAP kinase
Intraocular Pressure: The pressure of the fluids in the eye.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The aim of this study is to explore the effects of SB 202190, a highly selective p38 MAPK inhibitor, on bleb survival following glaucoma filtering surgery." | 3.81 | A p38 MAPK inhibitor improves outcome after glaucoma filtration surgery. ( Grisanti, S; Lüke, J; Lüke, M; Nassar, K; Tura, A, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Nassar, K | 1 |
| Tura, A | 1 |
| Lüke, J | 1 |
| Lüke, M | 1 |
| Grisanti, S | 2 |
1 other study available for sb 202190 and Intraocular Pressure
| Article | Year |
|---|---|
A p38 MAPK inhibitor improves outcome after glaucoma filtration surgery.
Topics: Animals; Cell Movement; Cell Proliferation; Cells, Cultured; Disease Models, Animal; Enzyme Inhibito | 2015 |